Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Department
Adjust height of sidebar
KMap
Department
Az Health Sciences Division
18 active people
77 grants
Recent Grants
A Phase I/II, Randomized, Double-blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gen
2024
·
$1.1M
gene therapy,
neurodegenerative diseases,
clinical trial,
genetic disorders,
drug safety
A Phase Ill, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of a Single Administration Of Comp360 in Participants With Treatment-
2024
·
$994.4K
clinical trials,
pharmacology,
mental health,
neuroscience,
psychiatry
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have
2024
·
$964K
clinical trials,
dermatology,
immunology,
inflammatory diseases,
pharmacology
Study to Evaluate Safety, Efficacy and Tolerability of ABBV-950 for the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients
2024
·
$822.1K
stroke rehabilitation,
spasticity treatment,
drug safety,
efficacy evaluation,
tolerability assessment
A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination with Background Therapy in Adult Participants with Pulmonary Arterial Hyp
2024
·
$555.7K
clinical trials,
pulmonary arterial hypertension,
drug efficacy,
safety evaluation,
combination treatment
A Phase 2b, Multinational, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Redasemtide (S-005151) Compared With Placebo in Adult Participants With Acute Ischemic Stroke Who Ar
2024
·
$470.3K
stroke,
clinical trial,
medication,
safety,
efficacy
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
2024
·
$440.6K
epilepsy,
medication,
clinical trial,
adjunctive therapy,
safety
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke
2024
·
$422.6K
neuroprotection,
stroke,
clinical trial,
thrombectomy,
pharmacology
Protocol Title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS)
2024
·
$370.5K
stroke,
drug efficacy,
safety evaluation,
clinical trial,
ischemic stroke
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult Participants With Moderate-Severe Atopic Dermatitis
2024
·
$290.8K
dermatology,
clinical trial,
immunology,
drug efficacy,
safety
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)
2024
·
$277.3K
clinical trials,
autoimmune diseases,
medication efficacy,
safety assessment,
immunology
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associate
2024
·
$270.6K
autoimmune diseases,
clinical trials,
immunology,
rheumatology,
drug administration
A Phase 2a Single-Arm, Open-Label, Exploratory Study to Assess the Effects of LAM-001 (Inhaled Sirolimus) for the Treatment of Pulmonary Hypertension
2024
·
$261.3K
pulmonary hypertension,
sirolimus,
inhaled therapy
A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pln-74809 (Bexotegrast) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)
2024
·
$221.6K
pulmonary fibrosis,
clinical trial,
drug efficacy,
safety evaluation,
dose-ranging
A Phase 1 Study to Evaluate the Efficacy and Safety Of AB-101, an Allogeneic Cord Blood Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III
2024
·
$141.8K
cell therapy,
immunotherapy,
cancer treatment,
clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Act
2024
·
$133.3K
clinical trials,
inflammatory bowel disease,
drug efficacy,
safety evaluation,
immunomodulatory therapy
A Phase 2, multicenter, Open-Label, Long-Term Safety Study of LP352 in Subjects with Developmental and Epileptic Encephalopathy who Completed Study LP352-201 and are Candidates for Continuous Treatmen
2024
·
$19.8K
epileptic encephalopathy,
long-term safety,
developmental disorders,
continuous treatment
A Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Biomarkers with Oral Colon Delivery
2024
·
$2.6K
clinical trial,
pharmacokinetics,
drug delivery,
safety assessment,
biomarkers
New Frontiers of Sound (NewFoS) Science and Technology Center
2023
·
$11.7M
sound science,
technology,
research center,
acoustic innovation,
interdisciplinary collaboration
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency?associated Liver Disease With Metavir
2023
·
$1.6M
clinical trial,
liver disease,
alpha-1 antitrypsin,
treatment,
safety
People
Alexandria Woods
Clinical Research Coordinator III
Alma Leon
Research Nurse III
Brent Gary
Clinical Research Coordinator II
Catherine Correia
Administrative Support Professional II
Daniel Duran
Clinical Research Coordinator I
David Elmer
Administrative Operations Manager V, Medicine
Austin Derma
Clinical Research Coordinator II
Gustavo Cornejo
Research Compliance Administrator III
Kirsten Anderson
Research Compliance Administrator IV
Kasi Kiehlbaugh
Academic Programs Officer III
Kaitlyn Ammann
Researcher/Scientist III
Maria Ambrose
Research Specialist, Senior
Matthew Briggs
Assistant Professor of Practice
Maria Gordon
Clinical Research Manager II
Nicole Marquez
Grant and Contract Administrator II
Pamela Ray
Financial Analysis Manager V
Ryan Yee
Grant and Contract Administrator III
Angela Souza
Campus Planning Manager IV
Research expenses history
Funding support
7 funding agencies since 2020
